Skip to content

Insomnia and affect

Insomnia and affect - Insomnia and affect

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON46531
Enrollment
190
Registered
2018-02-22
Start date
2018-12-06
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia depressive symptoms primary insomnia sleep problems

Interventions

Of the 130 people suffering from ID that participate in the RCT participants, at least 30 will be randomly assigned to one of the following three conditions: CBT-I, CT or CBT-I combined with CT. It

Sponsors

VU Medisch Centrum, Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Participants have to be at least 18 years old and less than 70 years old. - Additional inclusion criteria for the insomnia group specifically: * a diagnosis of insomnia according to the International Classification of Sleep Disorders (ICSD-2) * an Insomnia Severity Index score (ISI) *10 - Additional inclusion criteria for the RCT specifically: * a high score on the ISQ (cut-off to be determined).

Exclusion criteria

Exclusion criteria: - a current clinical diagnosis of major depressive disorder or a diagnosis of major depressive (DSM-4) assessed with the Composite International Diagnostic Interview * Short Form (CIDI-SF) - Diagnosed sleep apnea syndrome (OSAS) (AHI >15), restless leg syndrome (RLS) or periodic limb movement (PLMD) (PLMI > 25). Using the screening survey, we will exclude candidates with moderate to very severe RLS according to an IRLS scale score > 15 and candidates with a high risk of OSAS according to the Berlin questionnaire. In candidates suspect for PLMD according to the Duke Structured Interview for Sleep Disorders, the PLMI will be determined from the polysomnographic recordings of the pre-assessment; cases with a PLMI of 25 or more will be advised to consult a sleep specialist. - a known eye condition incompatible with light exposure - a history of light-induced migraine or epilepsy, or severe side effects to bright light in the past. - MRI contraindications such as non-MR compatible metal implants, claustrophobia, pregnancy * Current treatment with antidepressant medication * Night work or rotating shift-work

Design outcomes

Primary

MeasureTime frame
The primary outcome of the RCT is the severity of depressive symptoms during one year following the treatment. Depressive symptoms are measured with the Inventory of Depressive Symptomatology Self Report (IDS-SR). The primary effect of interest is the integrated treatment effect on IDS-SR at T1 to T4 relative to T0.

Secondary

MeasureTime frame
A secondary endpoint is a diagnosis of Depression based on a Composite International Diagnostic Interview * Short Form (CIDI-SF), which will be performed at baseline (to exclude patients with a DSM-5 depression diagnosis) and at 12 months. Other secondary outcome measures of the RCT are the severity of insomnia and the cost-effectiveness of each treatment calculated form health care and work absenteeism. Severity of insomnia will be measured with the Insomnia Severity Index (ISI), Consensus Sleep Diary (CSD) and actigraphy recordings. Cost-effectiveness will be asses with the Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness (TIC-P).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)